New combo therapy shows promise for Tough-to-Treat lymphoma

NCT ID NCT03927105

Completed Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatments. The goal was to see if the drug pair could shrink tumors. The trial is now complete, and the results help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States
Unviersity of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.